Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02981524 · ClinicalTrials.gov registry record · Phase 2
Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT02981524 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 17 participants.
The verdict
NCT02981524, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
This study will be looking at the objective response rate (ORR) as measured by RECIST in in patients with mismatch repair-proficient (MMR-p), advanced colorectal cancer that treated with CY/GVAX in combination with Pembrolizumab.
Interventions
- DRUG Pembrolizumab
- DRUG CY
- BIOLOGICAL GVAX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2017-05-26 |
| Est. Completion | 2018-03-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02981524
The ClinicalTrials.gov registry entry for NCT02981524 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT02981524 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02981524 about?
NCT02981524 is a clinical study titled "Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer". This study will be looking at the objective response rate (ORR) as measured by RECIST in in patients with mismatch repair-proficient (MMR-p), advanced colorectal cancer that treated with CY/GVAX in combination with Pembrolizumab.
What is the current status of trial NCT02981524?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2017-05-26. Estimated completion is 2018-03-20.
What interventions are being tested in trial NCT02981524?
The interventions under investigation include: Pembrolizumab (DRUG), CY (DRUG), GVAX (BIOLOGICAL).
Who is sponsoring clinical trial NCT02981524?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.